{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:44:45Z","timestamp":1787669085928,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"DOI":"10.1007\/s12664-024-01720-0","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:20:03Z","timestamp":1738999203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases \u2013 A meta-analysis of randomized controlled trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0030-9193","authenticated-orcid":false,"given":"Bruna Thaytala Quintino","family":"Falcon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamires","family":"de Mello Guimaraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele Alves","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisa","family":"de Mello Guimaraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"1720_CR1","doi-asserted-by":"crossref","unstructured":"Baumgart DC, ed. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. 2nd ed. Cham, Switzerland: Springer Nature; 2017.","DOI":"10.1007\/978-3-319-33703-6"},{"key":"1720_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.","journal-title":"Nat Rev Dis Primers"},{"key":"1720_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6:22.","journal-title":"Nat Rev Dis Primers"},{"key":"1720_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ibd\/izy015","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Keefer L, Wilding H, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses\u2014Part II. Inflamm Bowel Dis. 2018;24:966\u201376.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 2","key":"1720_CR5","first-page":"51","volume":"60","author":"C Harris","year":"2021","unstructured":"Harris C, Cummings J. Jak1 inhibition and inflammatory bowel disease. Rheumatology (Oxford). 2021;60 Suppl 2:51.","journal-title":"Rheumatology (Oxford)"},{"key":"1720_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/j.gastro.2022.02.013","volume":"162","author":"AL Hart","year":"2022","unstructured":"Hart AL, Rubin DT. Entering the era of disease modification in inflammatory bowel disease. Gastroenterology. 2022;162:1367\u20139.","journal-title":"Gastroenterology"},{"key":"1720_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","volume":"19","author":"I Marafini","year":"2019","unstructured":"Marafini I, Sedda S, Dinallo V, Monteleone G. Inflammatory cytokines: From discoveries to therapies in IBD. Expert Opin Biol Ther. 2019;19:1207\u201317.","journal-title":"Expert Opin Biol Ther"},{"key":"1720_CR8","doi-asserted-by":"crossref","unstructured":"Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355.","DOI":"10.1177\/1756283X17750355"},{"key":"1720_CR9","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF.\u00a0Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.","journal-title":"Clin Transl Gastroenterol"},{"key":"1720_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2468-1253(19)30414-5","volume":"5","author":"UN Shivaji","year":"2020","unstructured":"Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol. 2020;5:850\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1720_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","volume":"66","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199\u2013209.","journal-title":"Gut"},{"key":"1720_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pharmthera.2018.07.003","volume":"192","author":"C Soendergaard","year":"2018","unstructured":"Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH.\u00a0Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018;192:100\u201311.","journal-title":"Pharmacol Ther"},{"key":"1720_CR13","doi-asserted-by":"publisher","first-page":"108402","DOI":"10.1016\/j.pharmthera.2023.108402","volume":"245","author":"OH Nielsen","year":"2023","unstructured":"Nielsen OH, Boye TL, Gubatan J, Chakravarti D, Jaquith JB, LaCasse EC. Selective JAK1 inhibitors for the treatment of inflammatory bowel disease. Pharmacol Ther. 2023;245:108402.","journal-title":"Pharmacol Ther"},{"key":"1720_CR14","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1053\/j.gastro.2020.04.034","volume":"160","author":"TL Parigi","year":"2021","unstructured":"Parigi TL, D\u2019Amico F, Danese S. Upadacitinib for Crohn\u2019s disease and ulcerative colitis treatment: hitting the selective JAKpot. Gastroenterology. 2021;160:1472\u20134.","journal-title":"Gastroenterology"},{"key":"1720_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","volume":"68","author":"S Danese","year":"2019","unstructured":"Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68:1893\u20139.","journal-title":"Gut"},{"key":"1720_CR16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology. 2020;158:2123\u201338.e8.","journal-title":"Gastroenterology"},{"key":"1720_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"key":"1720_CR18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139\u201349.e14.","journal-title":"Gastroenterology"},{"key":"1720_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328.","journal-title":"Lancet"},{"key":"1720_CR20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, et al. Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023;21:1913\u201323.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"1720_CR21","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/ibd\/izac247.155","volume":"29","author":"J Levine","year":"2023","unstructured":"Levine J, McKibbin J, Ham R, et al. Use of upadacitinib in 11 tofacitinib-refractory ulcerative colitis patients at a single tertiary care center. Inflamm Bowel Dis. 2023;29 Suppl 1:S81.","journal-title":"Inflamm Bowel Dis"},{"key":"1720_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/ecco-jcc\/jjac157","volume":"17","author":"R Chugh","year":"2023","unstructured":"Chugh R, Braga-Neto MB, Fredrick TW, et al. Multicentre real-world experience of upadacitinib in the treatment of Crohn\u2019s disease. J Crohns Colitis. 2023;17:504\u201312.","journal-title":"J Crohns Colitis"},{"key":"1720_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10620-022-07582-w","volume":"68","author":"C Traboulsi","year":"2023","unstructured":"Traboulsi C, Ayoub F, Silfen A, Rodriguez TG, Rubin DT. Upadacitinib is safe and effective for Crohn\u2019s disease: real-world data from a tertiary center. Dig Dis Sci. 2023;68:385\u20138.","journal-title":"Dig Dis Sci"},{"key":"1720_CR24","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","volume":"21","author":"L Boneschansker","year":"2023","unstructured":"Boneschansker L, Ananthakrishnan AN; Massachusetts general hospital crohn\u2019s and colitis center collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data. Clin Gastroenterol Hepatol. 2023;21:2427\u20139.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1720_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med."},{"key":"1720_CR26","unstructured":"US Food and Drug Administration. Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an increased risk of blood clots and death with higher dose [press release]. Published July 26, 2019."},{"key":"1720_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"1720_CR28","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384.","journal-title":"Lancet"},{"key":"1720_CR29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/apt.17379","volume":"57","author":"S Din","year":"2023","unstructured":"Din S, Selinger CP, Black CJ, Ford AC. Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57:666\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"1720_CR30","doi-asserted-by":"publisher","first-page":"111229","DOI":"10.1016\/j.intimp.2023.111229","volume":"126","author":"D Zheng","year":"2024","unstructured":"Zheng D, Wang Y, Huang Y, Jiang M, Dai C. Effectiveness and safety of upadacitinib for inflammatory bowel disease: a systematic review and meta-analysis of RCT and real-world observational studies. Int Immunopharmacol. 2024;126:111229.","journal-title":"Int Immunopharmacol"},{"key":"1720_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40261-024-01364-0","volume":"44","author":"C Niu","year":"2024","unstructured":"Niu C, Zhang J, Napel M, et al.\u00a0Systematic review with meta-analysis: Efficacy and safety of Upadacitinib in managing moderate-to-severe Crohn\u2019s disease and ulcerative colitis. Clin Drug Investig. 2024;44:371\u201385.","journal-title":"Clin Drug Investig"},{"key":"1720_CR32","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ."},{"key":"1720_CR33","doi-asserted-by":"crossref","unstructured":"Falcon BF, Guimaraes TM, Halpern GA, et al. Insights into the safety profile of upadacitinib in inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. INPLASY Protocol. 2024; INPLASY202450040.","DOI":"10.37766\/inplasy2024.5.0040"},{"key":"1720_CR34","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2020.","DOI":"10.1002\/9781119536604"},{"issue":"Suppl 2","key":"1720_CR35","doi-asserted-by":"publisher","first-page":"S737","DOI":"10.1093\/ecco-jcc\/jjz202","volume":"14","author":"M Ferrante","year":"2020","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"J Crohns Colitis"},{"key":"1720_CR36","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Ferrante M, Sabino J. Efficacy of JAK inhibitors in ulcerative colitis. J Crohns Colitis. 2020;14 Suppl 2:S737.","journal-title":"Gastroenterology"},{"key":"1720_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000518264","volume":"6","author":"M Sutter","year":"2021","unstructured":"Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554\u201373.e12.","journal-title":"Inflamm Intest Dis"},{"key":"1720_CR38","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sutter M, Hruz P, Niess JH. High serum creatine kinase levels in infliximab and vedolizumab-treated inflammatory bowel disease patients. Inflamm Intest Dis. 2021;6:165\u201374.","journal-title":"BMJ."}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01720-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-024-01720-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01720-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:20:12Z","timestamp":1738999212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-024-01720-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":38,"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1007\/s12664-024-01720-0","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis was based on publicly available data from previously published studies, no new human participants were involved and therefore, ethical approval was not required. All original studies included in the analysis had obtained ethical approval and informed consent, as indicated in their respective publications and\/or protocols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This meta-analysis utilized data from previously published studies that stated to have obtained ethical approval and adhered to ethical standards regarding research involving human participants. No new human data were collected and the analysis was conducted using publicly available information, ensuring compliance with ethical guidelines for secondary research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"All authors consent to the publication of this manuscript and agree to be accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}